East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Abatacept
Orencia
Routinely available
NICE (TA373 (SMC 618/10))
07/03/2012

Indication

In combination with methotrexate, abatacept is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other disease modifying antirheumatic drugs (DMARDs) incl...

In combination with methotrexate, abatacept is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other disease modifying antirheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor. It has not been studied in children under 6 years old.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

250mg powder for concentrate for solution for injection

Comments

March 2012 - Added to the Additional List, for Specialist Use only. December 2015 - NICE MTA advice: SMC advice 618/10 is superseded by NICE TA373. July 2019 (as per LJF) - Routinely available in line with national guidance. Included on the Additional List, for Specialist Use only.

Link to Advice

TA373 (SMC 618/10)

Advice Published

16/12/2015